Spotlight on Dermatology
Improving the Treatment of Chronic Spontaneous Urticaria: What Does the Future Hold?
StartActivity Details
0.5 ABIM MOC Point(s)
Expires: December 7, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
- Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
- Assess current safety and efficacy data on emerging therapies for the treatment of CSU
Activity Description
In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.
Faculty

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
Autumn Burnette, MD, FACAAI, has relevant financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pfizer, Pharming, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, AstraZeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).
David M. Lang, MD, has relevant financial relationships with AstraZeneca, Sanofi Regeneron (Speaker/Speaker’s Bureau); Genentech, Gilead, Novartis, Sanofi Regeneron (Researcher).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.5 ABIM MOC Point(s)
Expires: December 7, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
- Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
- Assess current safety and efficacy data on emerging therapies for the treatment of CSU
Activity Description
In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.
Faculty

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
Autumn Burnette, MD, FACAAI, has relevant financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pfizer, Pharming, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, AstraZeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).
David M. Lang, MD, has relevant financial relationships with AstraZeneca, Sanofi Regeneron (Speaker/Speaker’s Bureau); Genentech, Gilead, Novartis, Sanofi Regeneron (Researcher).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Dermatology Presentations

Improving the Treatment of Chronic Spontaneous Urticaria: What Does the Future Hold?
StartActivity Details
0.5 ABIM MOC Point(s)
Expires: December 7, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
- Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
- Assess current safety and efficacy data on emerging therapies for the treatment of CSU
Activity Description
In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.
Faculty

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
Autumn Burnette, MD, FACAAI, has relevant financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pfizer, Pharming, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, AstraZeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).
David M. Lang, MD, has relevant financial relationships with AstraZeneca, Sanofi Regeneron (Speaker/Speaker’s Bureau); Genentech, Gilead, Novartis, Sanofi Regeneron (Researcher).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.5 ABIM MOC Point(s)
Expires: December 7, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Employ current management approaches for patients with chronic spontaneous urticaria (CSU)
- Identify elements of type 2 inflammation that play a role in CSU pathogenesis that may be amenable to treatment
- Assess current safety and efficacy data on emerging therapies for the treatment of CSU
Activity Description
In this activity, a panel of experts discuss the current guideline-recommended treatment approach to chronic spontaneous urticaria (CSU), with a focus on treatment of patients with refractory disease requiring third-line therapy. The panel will also discuss advances in understanding the pathogenesis of disease, the role of type 2 inflammation, and emerging therapies.
Faculty

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC

Professor and Chair, Medicine
Department of Allergy and Clinical Immunology
Respiratory Institute
Cleveland, OH
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Jonathan A. Bernstein, MD, has relevant financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Ionis, Genentech, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
Autumn Burnette, MD, FACAAI, has relevant financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pfizer, Pharming, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, AstraZeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).
David M. Lang, MD, has relevant financial relationships with AstraZeneca, Sanofi Regeneron (Speaker/Speaker’s Bureau); Genentech, Gilead, Novartis, Sanofi Regeneron (Researcher).
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Overcoming Diagnostic Barriers in Chronic Spontaneous Urticaria
StartActivity Details
0.25 ABIM MOC Point(s)
Expires: November 28, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose chronic spontaneous urticaria (CSU) via ready-symptom recognition and evidence-based practices
Activity Description
In this activity, a panel of experts discusses overcoming diagnostic barriers in chronic spontaneous urticaria (CSU) through a discussion of the patient’s journey, delays in diagnosis, and review of guideline-recommended approaches to diagnosis and assessment of disease activity.
Faculty

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Jonathan A. Bernstein, MD, has financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Genentech, Ionis, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
Autumn Burnette, MD, FACAAI, has financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pharming, Pfizer, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, Astra Zeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 ABIM MOC Point(s)
Expires: November 28, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for dermatologist and allergy/immunologist clinicians (MD/DO/NP/PA) who treat patients with chronic spontaneous urticaria (CSU).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Diagnose chronic spontaneous urticaria (CSU) via ready-symptom recognition and evidence-based practices
Activity Description
In this activity, a panel of experts discusses overcoming diagnostic barriers in chronic spontaneous urticaria (CSU) through a discussion of the patient’s journey, delays in diagnosis, and review of guideline-recommended approaches to diagnosis and assessment of disease activity.
Faculty

Professor, Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology/Allergy Section and
Bernstein Allergy Group
Bernstein Clinical Research Center
Cincinnati, OH

Assistant Professor, Division of Allergy and Immunology
Howard University Hospital
Washington, DC
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Jonathan A. Bernstein, MD, has financial relationships with AstraZeneca, BioCryst, BioMarin, Blueprint Medicine, Celldex, CSL Behring, Genentech, Ionis, Novartis, Pharming, Pharvaris, Sanofi Regeneron, Takeda/Shire (Consultant and Researcher); AstraZeneca, BioCryst, CSL Behring, Genentech, GSK, Novartis, Pharming, Sanofi Regeneron, Takeda/Shire (Speaker/Speaker’s Bureau).
Autumn Burnette, MD, FACAAI, has financial relationships with Amgen, AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, GSK, Pharming, Pfizer, Sanofi Genzyme and Regeneron, Takeda (Speaker/Speaker’s Bureau); AbbVie, BioCryst Pharmaceuticals, CSL Behring, GSK, Lilly, Sanofi Genzyme and Regeneron (Consultant); ALK, Amgen, Astra Zeneca, CSL Behring, Sanofi Genzyme and Regeneron (Advisor).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC
planners and managers have no relevant financial relationship(s) with
ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

A Learner Pathway in Moderate-to-Severe AD – Challenging Cases in Atopic Dermatitis: Managing Pediatric Patients and Adults with Multiple Comorbidities
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: October 26, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).
Learning Objectives
After completing this activity, the clinician should be able to:
- Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD)
- Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD
- Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD
Activity Description
In this activity, 2 atopic dermatitis (AD) experts, a dermatologist and dermatology PA, discuss challenging cases that have been submitted by physicians across the country. These AD cases will focus on evidence-based interprofessional management of pediatric patients and adults with multiple atopic comorbidities, including preventing flares and the unique roles of the interprofessional healthcare team.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Peter A. Lio, MD, FAAD, has financial relationship(s) with
AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN
Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis,
Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO
Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or
Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi
Genzyme, Theraplex, Unilever, Verrica, YobeeCare (Consultant);
AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly,
Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi
Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos,
YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM
(an OTC product) (Other, Patent Pending).
Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: October 26, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).
Learning Objectives
After completing this activity, the clinician should be able to:
- Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD)
- Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD
- Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD
Activity Description
In this activity, 2 atopic dermatitis (AD) experts, a dermatologist and dermatology PA, discuss challenging cases that have been submitted by physicians across the country. These AD cases will focus on evidence-based interprofessional management of pediatric patients and adults with multiple atopic comorbidities, including preventing flares and the unique roles of the interprofessional healthcare team.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Peter A. Lio, MD, FAAD, has financial relationship(s) with
AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN
Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis,
Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO
Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or
Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi
Genzyme, Theraplex, Unilever, Verrica, YobeeCare (Consultant);
AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly,
Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi
Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos,
YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM
(an OTC product) (Other, Patent Pending).
Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

A Learner Pathway in Moderate-to-Severe AD – Challenging Cases in Atopic Dermatitis: Managing Patients with Comorbid Asthma
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: October 26, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).
Learning Objectives
After completing this activity, the clinician should be able to:
- Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD)
- Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD
- Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD
Activity Description
In this activity, a panel of interprofessional atopic dermatitis experts discuss challenging cases that have been submitted by physicians across the country. These atopic dermatitis cases will focus on evidence-based interprofessional management of patients with severe disease and comorbid asthma, including step care, misdiagnosis, and improving patient adherence.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Peter A. Lio, MD, FAAD, has financial relationship(s) with
AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN
Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis,
Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO
Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or
Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi
Genzyme, Theraplex, Unilever, Verrica, YobeeCare (Consultant);
AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly,
Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi
Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos,
YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM
(an OTC product) (Other, Patent Pending).
Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: October 26, 2022
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).
Learning Objectives
After completing this activity, the clinician should be able to:
- Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD)
- Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD
- Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD
Activity Description
In this activity, a panel of interprofessional atopic dermatitis experts discuss challenging cases that have been submitted by physicians across the country. These atopic dermatitis cases will focus on evidence-based interprofessional management of patients with severe disease and comorbid asthma, including step care, misdiagnosis, and improving patient adherence.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Peter A. Lio, MD, FAAD, has financial relationship(s) with
AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN
Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis,
Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO
Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or
Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi
Genzyme, Theraplex, Unilever, Verrica, YobeeCare (Consultant);
AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly,
Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi
Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos,
YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM
(an OTC product) (Other, Patent Pending).
Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the post-test
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

SSc-ILD Podcast Series: Clinical Updates to Manage a Rare Lung Condition
StartActivity Details
Expires: August 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
- Review treatment options based on clinical evidence and expert guidelines.
- Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.
Activity Description
In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.
Statement of Educational Need
Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.
Agenda
Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty
Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland
Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty
Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland
Activity Chair

Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon
Faculty

Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim

Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH
Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: August 30, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, rheumatologists, dermatologists, and other health care professionals involved in the management of patients with systemic sclerosis-associated interstitial lung disease.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Examine the prevalence, risk factors, and disease course of systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- Evaluate strategies to ensure timely screening and monitoring for early diagnosis of patients with SSc-ILD.
- Review treatment options based on clinical evidence and expert guidelines.
- Assess communication strategies to help facilitate effective management, self-care and adherence in patients with SSc-ILD.
Activity Description
In this 4-part podcast series, expert faculty review best practices for the screening and diagnosis of systemic sclerosis-associated interstitial lung disease (SSc-ILD). They will also review the current and emerging therapies and the clinical evidence supporting their use in SSc-ILD.
Statement of Educational Need
Systemic sclerosis (SSc) is a rare multisystem autoimmune disorder with estimated incidence and prevalence estimates in the United States of 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively. In SSc, sclerosis of the skin, vasculopathy, and damage to internal organs including the lungs develop results from a complex interplay between vascular injury, fibrotic processes and immunological pathways. Lung involvement is the leading cause of SSc-associated death. Lung fibrosis develops in 80% of patients, and 25% to 30% develop progressive interstitial lung disease (ILD), leading to a 10-year mortality of up to 40% in those affected. It is thus crucial that clinicians can recognize and diagnose SSc-associated ILD (SSc-ILD) early to initiate appropriate therapy in a timely manner. Clinicians must also be abreast of the most recent treatment guidelines and the current and emerging therapies for SSc-ILD so they can plan optimal treatment plans for their patients.
Agenda
Understanding SSc-ILD: Prevalence and Burden of Disease With Drs. Elizabeth Volkmann and Kevin Flaherty
Diagnosis of SSc-ILD: Screening and Monitoring of Lung Function With Drs. Elizabeth Volkmann and Kristin Highland
Management of SSc-ILD: Guidelines and Treatment Options With Drs. Elizabeth Volkmann and Kevin Flaherty
Improving Adherence: Patient Engagement and Education With Drs. Elizabeth Volkmann and Kristin Highland
Activity Chair

Associate Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
Los Angeles, CA
Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Boehringer Ingelheim
Contracted Research: Kadmon
Faculty

Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Disclosure: Consulting Fee: Arrowhead, AstraZeneca, Bellerophon, Boehringer Ingelheim, DevPro, FibroGen, Horizon, Lupin, Pliant, Polarean, PureHealth, PureTech, Respivant, Shionogi, Sun, United Therapeutics
Contracted Research: Boehringer Ingelheim

Director, Rheumatic Lung Disease Program
Cleveland Clinic
Cleveland, OH
Disclosure: Consulting Fee: Boehringer Ingelheim
Speakers Bureau: Actelion, Bayer, Boehringer Ingelheim, United Therapeutics
Contracted Research: Acceleron, Actelion, Bayer, Boehringer Ingelheim, Gossamer Bio, United Therapeutics, Viela Bio
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
ADA Compliance
In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to CME@VindicoCME.com. Requests will be honored within 3-5 business days.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com

Emerging JAK Inhibitors for the Treatment of Atopic Dermatitis
StartActivity Details
Expires: August 22, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists and other health care professionals involved in the management of patients with atopic dermatitis.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Identify patients with atopic dermatitis (AD) who may benefit from topical therapy.
- Examine the latest clinical evidence regarding emerging Janus kinase (JAK) inhibitors in late-stage development for the management of patients with AD.
- Assess how emerging JAK inhibitors could be included into existing treatment paradigms for adolescents and adults with AD.
Activity Description
Nearly 70% of patients with atopic dermatitis (AD) have mild disease, which in most cases can be managed in the primary care setting with basic skin care management and topical agents. Patients with moderate-to-severe AD are notoriously more difficult to treat. Until recently, systemic steroids were the only treatment option, and they have limited efficacy with a poor safety profile. Emerging options with novel mechanisms of action are showing promise in late-stage clinical trials. Janus kinase inhibition is being thoroughly investigated in both topical and oral deliveries. In this continuing education activity, expert clinicians discuss why newer therapies are needed for AD.
Activity Description
Introduction
Patient Selection and Standard of Care for Atopic
Dermatitis
Eric L. Simpson, MD, MCR
Back to Basics: Mechanisms of Action of Therapies for Atopic
Dermatitis
Amy S. Paller, MS, MD
Management of Atopic Dermatitis: Current and Emerging
Therapies
Lawrence F. Eichenfield, MD
Panel Discussion
Conclusion
Activity Chair

Chief, Pediatric and Adolescent Dermatology
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego School of Medicine
Rady Children’s Hospital San Diego
San Diego, CA
Disclosures:
Consulting Fee: AbbVie, Almirall, Arcutis Biotherapeutics, Arena, Dermavant, Dermira, Forte Biosciences, Galderma, Incyte, Lilly, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, Sanofi Genzyme
Contracted Research: AbbVie, Dermira, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi Genzyme, Valeant
Faculty

Walter J. Hamlin Professor and Chair, Department of Dermatology
Professor, Department of Pediatrics
The Feinberg School of Medicine of Northwestern University
Chicago, IL
Disclosures:
Consulting Fee: AbbVie, Arena, Bausch + Lomb, Bristol-Myers Squibb, Dermavant, Forte Biosciences, LEO Pharma, LifeMax, Lilly, Pfizer, Rapt, Regeneron, Sanofi
Contracted Research: AbbVie, Incyte, Janssen, Lilly, Regeneron, UCB

Frances J. Storrs, M.D. Medical Dermatology Professor
Professor of Dermatology, School of Medicine
Director of Clinical Studies, Department of Dermatology
Oregon Health & Science University
Portland, OR
Disclosures:
Consulting Fee: AbbVie, Amgen, Arena, Benevolent AI, BiomX, Bluefin Biomedicine, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen, Coronado, Dermira, Evidera, Excerpta Medica, Forte Biosciences, Incyte, Janssen, Kyowa Kirin, LEO Pharma, Lilly, Medscape, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, SPARC India
Contracted Research: AbbVie, Amgen, Incyte, Kyowa Kirin, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Tioga, Vanda
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Incyte Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: August 22, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists and other health care professionals involved in the management of patients with atopic dermatitis.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Identify patients with atopic dermatitis (AD) who may benefit from topical therapy.
- Examine the latest clinical evidence regarding emerging Janus kinase (JAK) inhibitors in late-stage development for the management of patients with AD.
- Assess how emerging JAK inhibitors could be included into existing treatment paradigms for adolescents and adults with AD.
Activity Description
Nearly 70% of patients with atopic dermatitis (AD) have mild disease, which in most cases can be managed in the primary care setting with basic skin care management and topical agents. Patients with moderate-to-severe AD are notoriously more difficult to treat. Until recently, systemic steroids were the only treatment option, and they have limited efficacy with a poor safety profile. Emerging options with novel mechanisms of action are showing promise in late-stage clinical trials. Janus kinase inhibition is being thoroughly investigated in both topical and oral deliveries. In this continuing education activity, expert clinicians discuss why newer therapies are needed for AD.
Activity Description
Introduction
Patient Selection and Standard of Care for Atopic
Dermatitis
Eric L. Simpson, MD, MCR
Back to Basics: Mechanisms of Action of Therapies for Atopic
Dermatitis
Amy S. Paller, MS, MD
Management of Atopic Dermatitis: Current and Emerging
Therapies
Lawrence F. Eichenfield, MD
Panel Discussion
Conclusion
Activity Chair

Chief, Pediatric and Adolescent Dermatology
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego School of Medicine
Rady Children’s Hospital San Diego
San Diego, CA
Disclosures:
Consulting Fee: AbbVie, Almirall, Arcutis Biotherapeutics, Arena, Dermavant, Dermira, Forte Biosciences, Galderma, Incyte, Lilly, Novartis, Ortho Dermatologics, Otsuka, Pfizer, Regeneron, Sanofi Genzyme
Contracted Research: AbbVie, Dermira, Galderma, Incyte, Lilly, Pfizer, Regeneron, Sanofi Genzyme, Valeant
Faculty

Walter J. Hamlin Professor and Chair, Department of Dermatology
Professor, Department of Pediatrics
The Feinberg School of Medicine of Northwestern University
Chicago, IL
Disclosures:
Consulting Fee: AbbVie, Arena, Bausch + Lomb, Bristol-Myers Squibb, Dermavant, Forte Biosciences, LEO Pharma, LifeMax, Lilly, Pfizer, Rapt, Regeneron, Sanofi
Contracted Research: AbbVie, Incyte, Janssen, Lilly, Regeneron, UCB

Frances J. Storrs, M.D. Medical Dermatology Professor
Professor of Dermatology, School of Medicine
Director of Clinical Studies, Department of Dermatology
Oregon Health & Science University
Portland, OR
Disclosures:
Consulting Fee: AbbVie, Amgen, Arena, Benevolent AI, BiomX, Bluefin Biomedicine, Boehringer Ingelheim, Boston Consulting Group, Collective Acumen, Coronado, Dermira, Evidera, Excerpta Medica, Forte Biosciences, Incyte, Janssen, Kyowa Kirin, LEO Pharma, Lilly, Medscape, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Genzyme, SPARC India
Contracted Research: AbbVie, Amgen, Incyte, Kyowa Kirin, LEO Pharma, Lilly, Merck, Novartis, Pfizer, Regeneron, Sanofi, Tioga, Vanda
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Incyte Corporation.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com

A Learner Pathway in Moderate-to-Severe AD: Assessing the Role of Interprofessional Collaboration for Improving Patient Care
StartActivity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 19, 2022
Provided By
Provided by RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).
Learning Objectives
After completing this activity, the clinician should be able to:
- Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD)
- Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD
- Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD
Activity Description
In this activity, an interprofessional panel of experts and a patient with atopic dermatitis (AD) engage in a video panel discussion on key issues central to treatment selection and interprofessional care and collaboration. The experienced patient also shares highlighted aspects of his/her care journey, with an emphasis on “teaching moments”.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Peter A. Lio, MD, FAAD, has financial relationships with
AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN
Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis,
Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO
Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or
Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi
Genzyme, Theraplex, Unilever, Verrica, YobeeCare, (Consultant);
AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly,
Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi
Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos,
YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM
(an OTC product) (Other, Patent Pending).
Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the posttest
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Expires: August 19, 2022
Provided By
Provided by RMEI Medical Education, LLC
Target Audience
This activity is intended for allergy/immunology, dermatology, and primary care clinicians (MD/NP/PA) who manage patients with atopic dermatitis (AD).
Learning Objectives
After completing this activity, the clinician should be able to:
- Employ key fundamentals related to the type 2 inflammatory cascade when managing moderate-to-severe atopic dermatitis (AD)
- Apply conventional and biologic management approaches when treating patients with moderate-to-severe AD
- Practice as a member of an interprofessional care team in the optimal management of moderate-to-severe AD
Activity Description
In this activity, an interprofessional panel of experts and a patient with atopic dermatitis (AD) engage in a video panel discussion on key issues central to treatment selection and interprofessional care and collaboration. The experienced patient also shares highlighted aspects of his/her care journey, with an emphasis on “teaching moments”.
Faculty

Clinical Assistant Professor, Dermatology & Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Physician Assistant, Dermatology
Medical Dermatology Associates of Chicago
Chicago, IL
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Faculty
Peter A. Lio, MD, FAAD, has financial relationships with
AbbVie, Almirall, Altus Labs, Amyris, AOBiome, Arbonne, ASLAN
Pharmaceuticals, Bodewell, Burt's Bees, Dermavant, Eli Lilly, Exeltis,
Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, KPAway, LEO
Pharmaceuticals, Level Ex, L'Oreal, Menlo Therapeutics, Micreos, My-Or
Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi
Genzyme, Theraplex, Unilever, Verrica, YobeeCare, (Consultant);
AbbVie, AOBiome, Regeneron/Sanofi Genzyme (Researcher); Eli Lilly,
Galderma, Incyte, LEO Pharmaceuticals, L'Oreal, Pfizer, Regeneron/Sanofi
Genzyme (Speaker/Speaker's Bureau); Altus Labs, KPAway, Micreos,
YobeeCare (Stock/Shareholder); Theraplex Company for Theraplex AIM
(an OTC product) (Other, Patent Pending).
Joy Logothetis, MMS, PA-C, has no relevant financial relationship(s) with ineligible companies to disclose.
Patient
Patient participating in this activity has no relevant financial
relationship(s) with ineligible companies to disclose.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Interprofessional Continuing Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.25 Interprofessional Continuing Education (IPCE) credit for
learning and change.
American Board of Internal Medicine Maintenance of
Certification
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 medical
knowledge MOC point(s) in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
In order to claim MOC points, users must:
- Provide ABIM ID and month/date of birth and score 75% or higher on the posttest
MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee to participate.
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.